icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Denver, Colorado
March 3-6 2024
Back grey_arrow_rt.gif
 
 
 
Semaglutide at CROI 2024
 
 
  CROI: Is the Weight Over?: GLP-1 Receptor Agonists Are Here - Background - (03/11/24) lecture by Todd Brown
 
the use of semagltude is found to cause muscle loss in PWH in these studies, as well as worsening already existing or causing facial & limb fat loss/lipoatrphy, this this becomes a concern for WPWH aging were muscle & fat changes or loss can be impactful.
 
• CROI: Impact of Semaglutide on Weight Change Among People with HIV: A Stratified Analysis by Baseline BMI - (03/11/24)
 
CROI: Effects of Semaglutide on Muscle Structure and Function in the SLIM Liver Study - (03/12/24)
 
• CROI: Semaglutide Lowers Some Inflammation Markers in HIV Lipohypertrophy - (03/12/24)
 
CROI: Effects of Semaglutide on Inflammation and Immune Activation in HIV-Associated Lipohypertrophy....people with severe lipoatrophy were excluded from study, so were diabetics & CVD - (03/11/24)
 
• CROI: Effects of Semaglutide on Muscle Structure and Function in the SLIM Liver Study - (03/12/24)
 
• CROI: Semaglutide Lowers Some Inflammation Markers in HIV Lipohypertrophy - (03/12/24)
 
• CROI: Low-Dose Semaglutide Cuts Weight, Triglycerides, and Glucose in HIV MASLD Group - (03/12/24)
 
• CROI: Race/Ethnicity and Risk of NAFLD and Clinically Significant Fibrosis in Persons Living with HIV - (03/12/24)
 
• CROI: NAFLD and Advanced Fibrosis Are Common in Adults With HIV and Associated With Unique Histology - (03/12/24)
 
CROI: Weight Loss 5.7% at 1 Year With Semaglutide in HIV - Mark Mascolini (03/11/24)
 
100 NATAP CROI Reports
Conference on Retroviruses
and Opportunistic Infections Virtual

Mar 3 -, Mar 6, 2024